<scp>Exenatide‐induced</scp> granulomatous panniculitis associated with poly(<scp>d,l</scp>‐<scp>lactide‐co</scp>‐glycolide)

Zhu, Caroline; Kwan, Eddie A.; Williams, Grant M.; Lewin-Smith, Michael R.; Lincoln, Mark S.; Lee, Abigail J.

doi:10.1111/cup.14193

Cited by 2 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The first article was a case report in which a 63-year-old woman presented with nodules on her abdomen. 14 These nodules were found to be caused by exenatide-induced granulomatous panniculitis. The second article was also a case report and found nodule development on the thigh of a 54-year-old man.…”

Section: Resultsmentioning

confidence: 99%

A meta-analysis of the incidence of acne vulgaris in patients treated with GLP-1 agonists

Ogunremi,

Ismail,

Dhami

et al. 2024

International Journal of Women’s Dermatology

View full text Add to dashboard Cite

Background: With the emerging popularity of GLP-1 receptor agonists, patients are noticing acne vulgaris side effects that are seemingly related to the concurrent treatment with the drug. Due to the correspondence between these drugs’ relatively recent emergence in the U.S. market and their high demand, it is important to investigate what is currently known in the literature so that patients can be properly informed. Objective: The aim of this study is to investigate the relationship, or lack thereof, between glucagon like peptide 1 (GLP-1) receptor agonist usage and acne-related side effects in patients. Methods: A web-based analysis of 6 GLP-1 receptor agonists (3 with a once-weekly dosing schedule, and 3 with a once-daily dosing schedule) was conducted on PubMed online database. Boolean criteria were used to narrow the search. Included in the meta-analysis were 45 research articles that fulfilled the search criteria. Results: The results of the search showed that from the following long-acting GLP-1 receptor agonists, dulaglutide, exenatide extended release, and semaglutide (Wegovy), no conclusive acne side effects were reported. In addition, the results also showed that from the following short-acting GLP-1 receptor agonists, liraglutide, lixisenatide, and semaglutide (Rybelsus), no conclusive acne side effects were reported. Limitations: Limitations of this study include a limited amount of literature regarding the relationship between GLP-1 agonists and acne vulgaris. Conclusion: It is unlikely that GLP-1 agonists themselves are directly responsible for the acne that some patients may develop during treatment. Rather, it is more probable that the weight loss yielded by treatment with these drugs may induce intrinsic physiologic and hormonal changes that induce or exacerbate acne vulgaris in such patients.

show abstract

Section: Resultsmentioning

confidence: 99%